Cargando…
Tocilizumab in COVID-19 therapy: who benefits, and how?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298007/ https://www.ncbi.nlm.nih.gov/pubmed/34303431 http://dx.doi.org/10.1016/S0140-6736(21)01380-5 |
| _version_ | 1783725972135084032 |
|---|---|
| author | Yang, Chengliang Zhao, Hedi |
| author_facet | Yang, Chengliang Zhao, Hedi |
| author_sort | Yang, Chengliang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8298007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82980072021-07-23 Tocilizumab in COVID-19 therapy: who benefits, and how? Yang, Chengliang Zhao, Hedi Lancet Correspondence Elsevier Ltd. 2021 2021-07-22 /pmc/articles/PMC8298007/ /pubmed/34303431 http://dx.doi.org/10.1016/S0140-6736(21)01380-5 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Yang, Chengliang Zhao, Hedi Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title | Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title_full | Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title_fullStr | Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title_full_unstemmed | Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title_short | Tocilizumab in COVID-19 therapy: who benefits, and how? |
| title_sort | tocilizumab in covid-19 therapy: who benefits, and how? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298007/ https://www.ncbi.nlm.nih.gov/pubmed/34303431 http://dx.doi.org/10.1016/S0140-6736(21)01380-5 |
| work_keys_str_mv | AT yangchengliang tocilizumabincovid19therapywhobenefitsandhow AT zhaohedi tocilizumabincovid19therapywhobenefitsandhow |